Anthracycline chemotherapy maintains a prominent role in treating many forms of cancer.
Cardiotoxic side effects limit their dosing and improved cancer outcomes expose the cancer …

Abstract Purpose of Review Cardiovascular disease is long-term complication of both
cancer and anti-cancer treatment and can have significant ramifications for health-related …

Anthracycline‐induced cardiotoxicity (AIC) persists as a significant cause of morbidity and
mortality in cancer survivors. Although many protective strategies have been evaluated …

Abstract The Hatter Cardiovascular Institute biennial workshop, originally scheduled for April
2020 but postponed for 2 years due to the Covid pandemic, was organised to debate and …

Due to its poor capacity for regeneration, the heart is particularly sensitive to the loss of
contractile cardiomyocytes. The onslaught of damage caused by ischaemia and reperfusion …

Aims Anthracycline-induced cardiotoxicity (AIC) is a serious adverse effect among cancer
patients. A central mechanism of AIC is irreversible mitochondrial damage. Despite major …

Cardiotoxicity is a major cause of high attrition rates among newly developed drugs.
Moreover, anti-cancer treatment-induced cardiotoxicity is one of the leading reasons of …

Background Remote ischemic conditioning (RIC) has been beneficial in laboratory studies
of anthracycline cardiotoxicity, but its effects in patients is not established. Objectives The …

Background Anthracycline cardiotoxicity is a concern in survivors of childhood cancers.
Recent evidence suggests that remote ischemic conditioning (RIC) may offer myocardial …

Eighty‐three breast cancer patients who underwent six cycles of EC chemotherapy regimen
(epirubicin+ cyclophosphamide) without symptoms and signs of heart disease were enrolled …